
Pfizer/BioNTech says its Covid-19 vaccine is 100% effective and well tolerated in adolescents
CNN
Clinical trial results of Pfizer/BioNTech's Covid-19 vaccine show it is 100% efficacious and well tolerated in youths 12-15.
Pfizer/BioNTech plan to submit the data to the US Food and Drug Administration as soon as possible for expanded emergency use authorization of the two-dose vaccine. In a Phase 3 trial of 2,260 participants ages 12 to 15 in the US, the vaccine elicited strong antibody responses one month after the second dose -- exceeding those demonstrated in people ages 16 to 25 in previous trials, Pfizer reported. The vaccine is currently authorized in the US for emergency use in people 16 and older.More Related News